WO2017017662A4 - Microorganism strain lactobacillus plantarum ls/07 ccm 7766, method of its use and food product - Google Patents
Microorganism strain lactobacillus plantarum ls/07 ccm 7766, method of its use and food product Download PDFInfo
- Publication number
- WO2017017662A4 WO2017017662A4 PCT/IB2016/054600 IB2016054600W WO2017017662A4 WO 2017017662 A4 WO2017017662 A4 WO 2017017662A4 IB 2016054600 W IB2016054600 W IB 2016054600W WO 2017017662 A4 WO2017017662 A4 WO 2017017662A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ccm
- lactobacillus plantarum
- microorganism strain
- strain lactobacillus
- product
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract 18
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract 16
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract 16
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract 16
- 235000013305 food Nutrition 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 8
- 210000001072 colon Anatomy 0.000 claims abstract 4
- 230000007423 decrease Effects 0.000 claims abstract 4
- 210000003736 gastrointestinal content Anatomy 0.000 claims abstract 4
- 244000005709 gut microbiome Species 0.000 claims abstract 4
- 102000004190 Enzymes Human genes 0.000 claims abstract 3
- 108090000790 Enzymes Proteins 0.000 claims abstract 3
- 241000894006 Bacteria Species 0.000 claims abstract 2
- 208000038016 acute inflammation Diseases 0.000 claims abstract 2
- 230000006022 acute inflammation Effects 0.000 claims abstract 2
- 235000012182 cereal bars Nutrition 0.000 claims abstract 2
- 208000037976 chronic inflammation Diseases 0.000 claims abstract 2
- 230000006020 chronic inflammation Effects 0.000 claims abstract 2
- 238000000855 fermentation Methods 0.000 claims abstract 2
- 230000004151 fermentation Effects 0.000 claims abstract 2
- 150000002632 lipids Chemical class 0.000 claims abstract 2
- 235000013622 meat product Nutrition 0.000 claims abstract 2
- 230000008092 positive effect Effects 0.000 claims abstract 2
- 239000000047 product Substances 0.000 claims 12
- 208000017667 Chronic Disease Diseases 0.000 claims 2
- 102000053187 Glucuronidase Human genes 0.000 claims 2
- 108010060309 Glucuronidase Proteins 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 235000013351 cheese Nutrition 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Invention concerns a microorganism strain Lactobacillus Plantarum LS/07 CCM 7766 and a method of its use for the purposes of adjustment and stabilization of healthy intestinal microflora of a man. Microorganism strain Lactobacillus Plantarum LS/07 CCM 7766 is isolated from a man and it is applied in the food products such as energetic cereal bars, diary and meat products and, preferably, pasteurized bryndza. The advantage of a new microorganism strain Lactobacillus Plantarum LS/07 CCM 7766 is the modulation effect of the used strain, which is manifested by the increase of the lactic fermentation bacteria and decrease of coliforms in the intestinal content of the colon. Application of the strain has effect not only on the intestinal microflora, but also on the metabolic activities with the positive effect on lipid profile. Strain Lactobacillus plantarum LS/07 CCM 7766 does not produce β-glucurinodase enzyme which can have carcinogenic effects, but it also decreases this enzyme's activity in the intestinal content, mainly during the acute or chronic inflammation of the colon.
Claims
AMENDED CLAIMS
received by the International Bureau on 27 January 2017 (27.01.2017)
A microorganism strain Lactobacillus Plantarum LS/07 CCM 7766, isolated from a human, which is deposited in the Czech collection of microorganisms at the Faculty of Science of the Masaryk University, Brno, Czech Republic for use during a modulation of an intestinal microflora and simultaneously for a prevention of inflammatory chronic diseases of humans.
A microorganism strain Lactobacillus Plantarum LS/07 CCM 7766, according to the claim 1 for use in the treatment against a pathogenic strain Escherichia coli.
A microorganism strain Lactobacillus Plantarum LS/07 CCM 7766, according to the claim 1 or 2 for metabolization of healthy substances without production of β- glucuronidase.
A microorganism strain Lactobacillus Plantarum LS/07 CCM 7766, according to any of the claims 1 to 3 for lowering of an activity of an enzyme of the β- glucuronidase in an intestinal content, mainly during acute and/or chronic inflammation of a colon.
A microorganism strain Lactobacillus Plantarum LS/07 CCM 7766, according to any of the claims 1 to 4 for increase of the number of lactic fermentation bacteria increases and simultaneous decrease of the number of coliforms in the intestinal content of the colon decreases with a positive effect on a lipid profile.
A microorganism strain Lactobacillus Plantarum LS/07 CCM 7766, according to any of the claims 1 to 5 for inhibition of pro-inflammatory cytokines IL-2, IL-17 and TNF-a.
A microorganism strain Lactobacillus Plantarum LS/07 CCM 7766, according to any of the claims 1 to 6 for support of a growth of an anti-inflammatory regulatory cytokines IL-10 and TGF-β.
Microorganism strain Lactobacillus Plantarum LS/07 CCM 7766 according to any of the claims 1 to 7 in a dried form.
Microorganism strain Lactobacillus Plantarum LS/07 CCM 7766 according claim 8 in a form of lyophylisate.
10. A product containing the microorganism strain Lactobacillus Plantarum LS/07 CCM 7766 according to any of the claims 1 to 9.
11. The product according to the claim 10 i s c h a r a c t e r i z e d b y t h e f a c t , that it is a fermented diary product.
12. The product according to the claim 10 i s c h a r a c t e r i z e d b y t h e f a c t , that it is a cheese.
13. The product according to the claim 10 i s c h a r a c t e r i z e d b y t h e f a c t , that it is an independent nutritional supplement, preferably in form of capsules.
14. The product according to the claim 10 i s c h a r a c t e r i z e d b y t h e f a c t , that it has a form of energetic cereal bars, diary and meat products.
15. The product according to any of the claims 10, 11, 12, 14 i s c h a r a c t e r i z e d b y t h e f a c t , that it is a pasteurized bryndza.
Statement under article 19(1)
The novelty according to IRS and written opinion of ISA was recognized for the second patent claim. The feature from the second cliam has been thus transferred to the first claim. This feature is not disclosed in the prior state of the art. The closest prior art consists of earlier academic publications of the inventors of this patent application. If the feature concerned (modulation of an intestinal microflora and for a prevention of inflammatory chronic diseases of humans) is not present even in that publication which discloses the same microorganism strain, then such feature cannot be considered common or easily deduced from the prior state of the art. Had the prior state of the art included relevant, similar but not identical microorganism strains, the person skilled in the art could have presumed that the features and effects of the related strain would vary in certain field. However, the scientific publications in the prior state of the art concerned the same, identical strain (that is why there was considered a lack of novelty in the general first claim), and nothing suggests to the person skilled in art to vary the effects of this strain over the scope of the publication. It is also crucial that Lactobacilli have in general a broad spectrum of effects and it is not possible to deduce new effects without inventive step.
Taking the abovementioned into account, we believe that the original claim 2, now merged with the original claim 1, does meet the criterion of inventive step, and that the given feature in the claim appears as common only in the inappropriate ex post facto analysis.
The inappropriate method claims 3 and 4 were reworked as product claims, whereby the respecitve product claims have been moved to the end as claims 13 to 15, where they more clearly elaborate upon the product claims. We have also unified the terms food product and nutritional supplement, preferably in form of capsules, used in claims 10 to 15, into the general term "product". Pursuante to the abovementioned, we also amend the title of the invention to: "Microorganism strain Lactobacillus Plantarum LS D7 CCM 7766, and product containing this strain".
Novelty of the claims 1 to 15 is now based on the result of the ISR and written opinion of ISA; claims 2 to 15 are dependent on the claim 1. Thanks to this dependence, we believe that cliams 2 to 15 also meet the criterion of inventive step.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SK50011-2018A SK500112018A3 (en) | 2015-07-30 | 2016-07-30 | Microorganism strains Lactobacillus Plantarum LS/07 CCM 7766, product containing this strains |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SKPP54-2015 | 2015-07-30 | ||
| SK54-2015A SK542015A3 (en) | 2015-07-30 | 2015-07-30 | Strains Lactobacillus Plantarum LS/07 CCM 7766 and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2017017662A1 WO2017017662A1 (en) | 2017-02-02 |
| WO2017017662A4 true WO2017017662A4 (en) | 2017-03-16 |
Family
ID=56943878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2016/054600 WO2017017662A1 (en) | 2015-07-30 | 2016-07-30 | Microorganism strain lactobacillus plantarum ls/07 ccm 7766, method of its use and food product |
Country Status (3)
| Country | Link |
|---|---|
| CZ (2) | CZ33363U1 (en) |
| SK (2) | SK542015A3 (en) |
| WO (1) | WO2017017662A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2369777B (en) * | 2000-10-05 | 2004-10-27 | St Ivel Ltd | Food products with antimicrobial lactic acid bacteria |
| EP1997499A1 (en) * | 2007-05-31 | 2008-12-03 | Puleva Biotech, S.A. | Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis |
| KR101255050B1 (en) * | 2009-07-14 | 2013-04-16 | 씨제이제일제당 (주) | Novel lactobacillus plantarum and compositions comprising the same |
-
2015
- 2015-07-30 SK SK54-2015A patent/SK542015A3/en not_active Application Discontinuation
-
2016
- 2016-07-30 WO PCT/IB2016/054600 patent/WO2017017662A1/en active Application Filing
- 2016-07-30 SK SK50011-2018A patent/SK500112018A3/en not_active Application Discontinuation
- 2016-07-30 CZ CZ2018-34733U patent/CZ33363U1/en not_active IP Right Cessation
- 2016-07-30 CZ CZ2018-101A patent/CZ2018101A3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017017662A1 (en) | 2017-02-02 |
| SK542015A3 (en) | 2017-02-02 |
| SK500112018A3 (en) | 2018-12-03 |
| CZ33363U1 (en) | 2019-11-12 |
| CZ2018101A3 (en) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Naghmouchi et al. | Lactobacillus fermentum: A bacterial species with potential for food preservation and biomedical applications | |
| Son et al. | Antioxidant and immunostimulatory effect of potential probiotic Lactobacillus paraplantarum SC61 isolated from Korean traditional fermented food, jangajji | |
| da Silva Sabo et al. | Overview of Lactobacillus plantarum as a promising bacteriocin producer among lactic acid bacteria | |
| Varsha et al. | 2, 4-Di-tert-butyl phenol as the antifungal, antioxidant bioactive purified from a newly isolated Lactococcus sp. | |
| Manimala et al. | In vitro antioxidant and antimicrobial activity of carotenoid pigment extracted from Sporobolomyces sp. isolated from natural source | |
| Xie et al. | Characterization of an anti-Listeria bacteriocin produced by Lactobacillus plantarum LB-B1 isolated from koumiss, a traditionally fermented dairy product from China | |
| Quattrini et al. | Functional characterization of Lactobacillus plantarum ITEM 17215: A potential biocontrol agent of fungi with plant growth promoting traits, able to enhance the nutritional value of cereal products | |
| Chifiriuc et al. | In vitro assay of the antimicrobial activity of kephir against bacterial and fungal strains | |
| Varsha et al. | Control of spoilage fungi by protective lactic acid bacteria displaying probiotic properties | |
| Aspri et al. | Raw donkey milk as a source of Enterococcus diversity: Assessment of their technological properties and safety characteristics | |
| EP4257194A3 (en) | Use of microbial communities for human and animal health | |
| MX2020013064A (en) | Lactobacillus plantarum for skin care. | |
| WO2019190146A3 (en) | Novel lactobacillus fermentum lm1016 strain, and composition for preventing or treating cardiovascular diseases | |
| CY1113187T1 (en) | ISOLATED STRAIN OF MICROORGANISM LACTOBACILLUS PLANTARUM TENSIA DSM 21380 AS antimicrobial and antihypertensive probiotic, FOOD AND COMPOSITION CONTAINING THE SAID MICRO-ORGANISM AND USE OF THIS MICROORGANISM FOR THE PRODUCTION OF A antihypertensives AND MEDOTHOS FOR THE SUPPRESSION OF PATHOGENIC AND Lactobacillus NOT USED AS Dough IN A FOOD | |
| Kariyawasam et al. | Synbiotic yoghurt supplemented with novel probiotic Lactobacillus brevis KU200019 and fructooligosaccharides | |
| Ojha et al. | Effect of high intensity ultrasound on the fermentation profile of Lactobacillus sakei in a meat model system | |
| RU2015129066A (en) | APPLICATION OF BIFIDOBACTERIUM ANIMALIS FOR THE TREATMENT OR PREVENTION OF WEIGHT AND INSULIN RESISTANCE | |
| Zaiton et al. | Effect of pH and heat treatment on antifungal activity of Lactobacillus fermentum Te007, Lactobacillus pentosus G004 and Pediococcus pentosaceus Te010 | |
| WO2019098810A3 (en) | Novel lactic acid bacteria and use thereof | |
| EA202090863A1 (en) | LACTOBACILLUS RHAMNOSUS WITH INCREASED PRODUCTION OF DIACETYL | |
| Denkova et al. | Antimicrobial activity of probiotic lactobacilli, bifidobacteria and propionic acid bacteria, isolated from different sources | |
| Saad et al. | Effect of pH, heat treatments and proteinase K enzyme on the activity of Lactobacillus acidophilus bacteriocin | |
| EA202190286A1 (en) | MICROBIOLOGICAL METHOD FOR PRODUCING PERGA | |
| FI20075539L (en) | Lactic acid bacteria with proinflammatory properties | |
| Rahimzadeh et al. | Comparison of two types of gels in improving burn wound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16767012 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PUV2018-34733 Country of ref document: CZ Ref document number: PV2018-101 Country of ref document: CZ Ref document number: PV2018-100 Country of ref document: CZ |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 16767012 Country of ref document: EP Kind code of ref document: A1 |